LATEST
NEWS
Venture Café London's Thursday Gathering - 26 de febrero de 2026
We're showcasing at Venture Café London’s Thursday Gathering, "From Research Gaps to...
Conozca al equipo AMELIE
The AMELIE YouTube channel is home to several video interviews where you can hear from members of...
AMELIE se presenta en el Gran Evento Intestinal 2024
The AMELIE research team was delighted to be invited to present at the Big Bowel Event on 22nd...
Destacamos la incontinencia fecal en el Journal of Cell and Gene Therapy Insights
The causes and impacts of faecal incontinence are being highlighted in the latest edition of the...
Cómo AMELIE podría abordar las necesidades no cubiertas en el tratamiento de la incontinencia fecal
Professor Charles Knowles, Clinical Chief Investigator of AMELIE Project, discusses our research...
Nuevos enfoques regenerativos para tratar la incontinencia fecal
Professor Richard Day is the Principal Investigator of the AMELIE project. He discusses how...
La encuesta AMELIE revela que la incontinencia fecal se considera un grave problema de salud pública
La incontinencia fecal (IF) es una enfermedad frecuente que afecta a unos 67 millones de personas en Europa. Muchas de estas personas pueden sufrir incontinencia a causa de una lesión, a menudo provocada por el parto. La investigación de AMELIE sobre medicina regenerativa y terapia celular pretende ayudar a estas personas. En el marco del proyecto AMELIE, hemos realizado una encuesta para conocer la opinión de la población sobre la incontinencia urinaria y la medicina regenerativa en distintos países europeos.
Hay que actuar para corregir las graves desigualdades en la atención sanitaria en los servicios de suelo pélvico del Reino Unido
Bowel Research UK welcomes the findings of a new report which reveals significant short-comings in the care of UK patients with pelvic floor disorders (PFDs), and provides recommendations on six areas for change to improve outcomes.
Los servicios de suelo pélvico del Reino Unido deben cambiar
A new report, ‘Seizing the opportunity to improve patient care: Pelvic Floor services in 2021 and beyond’ exposes significant shortcomings in the care of patients with pelvic floor disorders in the UK. It provides national and local recommendations to improve healthcare services.
¿Pueden las inyecciones de BOTOX ayudar a solucionar la incontinencia?
For millions of Britons it is a secret they dare not discuss. A problem they put up with, silently, often for decades. Incontinence will affect 40 per cent of women, and one in ten men at some point in their lives.
El Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz participa en un ensayo clínico sobre el tratamiento de la incontinencia fecal con terapia celular
Fecal incontinence is a disease that affects some 67 million people in Europe. Although severity and presentation may be compatible with social life, it often overrides it entirely.
The latest to combat fecal incontinence: cell therapy
Fecal incontinence (FI) affects one in 20 Europeans. Although the severity and the way it presents itself are not life-threatening, this condition often ends up nullifying the social relationships of the people who suffer from it. And, its management continues to be a challenge for Medicine because a definitive optimal treatment for it has not yet been determined.
In search of a therapy against the disease that most affects social life
There are people who manage to live with it, but for most suffering fecal incontinence is synonymous with completely ending their social life, the main consequence of suffering from one of the diseases that cause the most stigma, as shown by never talking or writing about it subject.
AMELIE project: a new clinical study for CVBF
We are happy to announce that CVBF will be involved in the new project AMELIE – Anchored Muscle cELIs for IncontinencE aimed to test a new clinical approach for the treatment of faecal incontinence (FI) arising from childbirth injury in women.














